These preliminary data suggest that R-tPA-related angioedema may result from abnormal immune cell activation, leading to increased release of vasoactive mediators. This immune dysregulation may contribute to the pathophysiology of angioedema in susceptible IS patients treated with R-tPA.
Palestra et al. (Wed,) studied this question.